Enoxaparin with acenocoumarol

PreclinicalSmall molecule

IInstitute of Liver and Biliary Sciences, India

Enoxaparin with acenocoumarol is one of 11 small molecule programs targeting Portal vein thrombosis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Portal Vein ThrombosisActive, not recruiting

Portal Vein ThrombosisPreclinical

Active, not recruiting

Competition

Competitive Landscape

11 competitors in Portal Vein Thrombosis

#DrugCompanyPhaseTrials

Eliquis

Bristol-Myers Squibb

Approved

4 2

Bayer Aspirin

Bayer

Approved

3 3

Coumadin

AAbbott

Approved

4 4

Persantine

Boehringer Ingelheim

Approved

3 5

Xarelto

WWim Janssens

Approved

1 6

Pradaxa

Boehringer Ingelheim

Phase 3

2 7

Lenvima

Eisai

Phase 2

1 8

Xifaxan

SSalix

Preclinical

1 9

Anticoagulation

HHospital Álvaro Cunqueiro

Preclinical

1 10

Non-Selective Beta-Blockers

UUniversity of California, Los Angeles

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Portal vein thrombosis1 trial

Efficacy and Safety of Acenocoumarol for Treatment of Nontumor Portal Vein Thrombosis in Cirrhosis of Liver

Withdrawn·IInstitute of Liver and Biliary Sciences, India·N/A·NCT01631877

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Enoxaparin with acenocoumarol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Enoxaparin with acenocoumarol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Enoxaparin with acenocoumarol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Institute of Liver and Biliary Sciences, India company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: IInstitute of Liver and Biliary Sciences, India

Enoxaparin with acenocoumarol

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Portal vein thrombosis1 trial

References

Drug Info

Quick Facts

Related News